A total of 152 deals were announced in the global healthcare sector, including pharmaceuticals and medical equipment, during the week ended 29 March 2020 according to GlobalData’s deals database.
The number represents an increase of 23.6% over the 123 deals announced during the previous week.
GlobalData analyst Aurojyoti Bose said: “While deal activity remained subdued globally on the back of volatile market conditions, due to the outbreak of the coronavirus (COVID-19), the healthcare sector showcased resillence and witnessed growth in deal activity after witnessing decline during previous two weeks.
“Deal activity remained mostly flat in China, while other key markets such as the US and the UK witnessed growth in deal activity during the week ended March 29.”
Announcement of equity offerings, licensing agreements, partnerships and private equity deals increased by 81.8%, 130%, 29.6% and 50%, respectively.
However, deals volume of venture financing and merger and acquisitions (M&A) declined by 25% and 50%, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.